{
    "data": [
        {
            "id": "4742693",
            "type": "article",
            "attributes": {
                "publishOn": "2024-12-06T13:50:52-05:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161348037/image_2161348037.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View",
                "structuredInsights": "{ \"Key Takeaways\": [ \"The article compares Johnson & Johnson (JNJ) and Amgen (AMGN) as dividend stocks, recommending JNJ as a stronger investment.\", \"JNJ is rated as 'Strong Buy' due to its generous yield, attractive valuation, stable inventory, and healthy growth potential.\", \"JNJ has a 62-year track record of dividend increases, significantly surpassing AMGN's 14-year record.\", \"JNJ's dividend yield is approximately 21% higher than its four-year average, indicating a valuation discount.\", \"JNJ's cash payout ratio is 57%, below its 5-year average of 59.7%, while AMGN's current ratio is 76%, above its 5-year average.\", \"\\\"Dividends, together with inventory data, provide the most direct and least ambiguous financial data in my mind to assess business fundamentals.\\\"\" ], \"Positives\": [ \"JNJ's dividend yield is 21% higher than its historical average, presenting an attractive valuation.\", \"JNJ's 62-year track record of consistent dividend growth demonstrates reliability and financial stability.\", \"Strong inventory management with JNJ requiring fewer inventory days compared to AMGN.\", \"\\\"Dividends don\u2019t lie. For stewards like JNJ, who has been paying/growing dividends for decades, I consider dividends the best window to peer into their future.\\\"\" ], \"Concerns\": [ \"Political and policy uncertainties with the nomination of Robert F. Kennedy Jr. as HHS Secretary.\", \"Both JNJ and AMGN have experienced stock price pressure due to recent political developments.\", \"Potential policy changes could negatively impact both JNJ and AMGN in the long term.\", \"\\\"Kennedy\u2019s appointment might continue pressuring the stock prices of both JNJ and AMGN in the near term, and also lead to policy changes...\\\"\" ], \"Catalysts\": [ \"New quarterly earnings reports for JNJ and AMGN provide insights into future performance.\", \"The nomination of Robert F. Kennedy Jr. as HHS Secretary could impact the healthcare sector.\", \"JNJ's strong dividend yield and valuation discount serve as compelling investment catalysts.\", \"\\\"Many other Seeking Alpha authors have detailed several aspects of these potential impacts.\\\"\" ] }",
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "588802",
                            "type": "sentiment"
                        },
                        {
                            "id": "588801",
                            "type": "sentiment"
                        },
                        {
                            "id": "588803",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4742693-johnson-and-johnson-better-dividend-stock-than-amgen-in-our-view"
            }
        },
        {
            "id": "4740737",
            "type": "article",
            "attributes": {
                "publishOn": "2024-11-27T13:06:58-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304818/image_1219304818.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You",
                "structuredInsights": "{ \"Key Takeaways\": [ \"The article discusses Amgen's MariTide advancing to Phase III, highlighting growth potential despite market skepticism.\", \"Phase II results showed 20% average weight loss in 52 weeks, competitive with tirzepatide but with shorter dosing duration.\", \"Despite adverse GI events, 90% of Phase II patients continued with the study, indicating potential patient acceptance.\", \"MariTide offers advantages like monthly dosing, potentially easing supply shortages and appealing in the type 2 diabetes market.\", \"Amgen's market cap is $150 billion compared to Eli Lilly and Novo Nordisk's combined $1.18 trillion, providing growth opportunity.\", \"\\\"Amgen remains a strong buy for long-term investors, with substantial upside due to its GLP-1 pipeline.\\\"\" ], \"Positives\": [ \"MariTide's Phase II results show robust weight loss, competitive with leading GLP-1 drugs.\", \"MariTide's extended dosing schedule may address supply shortages, enhancing its market potential.\", \"Amgen's strong manufacturing capabilities support rapid scaling in the expanding GLP-1 market.\", \"\\\"Amgen remains a strong buy for long-term investors, with substantial upside due to its GLP-1 pipeline.\\\"\" ], \"Concerns\": [ \"GI side effects in Phase II raised questions about patient preference over existing drugs.\", \"Discontinuation rates due to AEs were higher compared to tirzepatide's Phase III study.\", \"Uncertainty remains on whether MariTide's advantages outweigh existing GI side effects.\", \"\\\"A concerning level of GI toxicology was still observed, questioning patient preference over existing drugs.\\\"\" ], \"Catalysts\": [ \"Phase III development of MariTide is a significant growth catalyst for Amgen.\", \"Positive Phase II results increase the likelihood of FDA approval and market entry.\", \"Amgen's strategic focus on manufacturing and dosing could accelerate market share capture.\", \"\\\"Amgen's management remains fully confident that MariTide's differentiated profile can meaningfully address obesity and type II diabetes.\\\"\" ] }",
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "586746",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4740737-amgen-phase-2-results-not-bad-dont-let-mr-market-fool-you"
            }
        },
        {
            "id": "4740577",
            "type": "article",
            "attributes": {
                "publishOn": "2024-11-27T04:39:45-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204124144/image_1204124144.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Checks All The Wrong Boxes",
                "structuredInsights": "{ \"Key Takeaways\": [ \"The article discusses Amgen's current challenges, including a weakening pipeline and technical indicators suggesting continued stock pressure.\", \"Amgen, a leader in neutropenia drugs, faces market sentiment and emotional flux impacting future growth potential.\", \"Concerns include RFK Jr.'s potential influence on U.S. healthcare and recent disappointing drug trial results.\", \"Amgen's dividend yield does not meet my Yield At a Reasonable Price (YARP) criteria, making it less attractive.\", \"Profitability remains intact, but the stock's yield trend and technical damage signal potential further downside risk.\", \"\\\"Amgen remains on my 50-stock watchlist and I rate it sell simply because it is not a current consideration for me in the stock section.\\\"\" ], \"Positives\": [ \"Amgen's profitability is intact, keeping free cash flow above 30% of sales.\", \"Repatha, Amgen's cholesterol-lowering drug, continues to defend its wide moat.\", \"Despite headwinds, Amgen's newer drugs provide a balance against legacy product challenges.\", \"The yield is solid in a market lacking for high 3% names with quality, and the safety rating, which I also key on, is well above average.\" ], \"Concerns\": [ \"The weakening pipeline and disappointing trial data raise red flags for future growth.\", \"Technical indicators suggest continued stock pressure and potential downside risk.\", \"Yield trends and market sentiment pose significant challenges to Amgen's stock appeal.\", \"Amgen's dividend yield, when viewed through the lens of my Yield At a Reasonable Price (YARP) factor, is one of those \\\"wrong boxes\\\" I referred to in the title of this article.\" ], \"Catalysts\": [ \"Potential changes in U.S. healthcare policy could impact Amgen's market position.\", \"Disappointing phase 2 data on MariTide influences market sentiment negatively.\", \"Patent expirations and reimbursement hurdles pose challenges to Amgen's revenue.\", \"But if that does happen, Amgen could rise to the upper end of my watchlist, if the core story is intact (likely discounted valuation combined with a growth catalyst).\" ] }",
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59801",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "586595",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4740577-amgen-checks-all-the-wrong-boxes"
            }
        },
        {
            "id": "4740464",
            "type": "article",
            "attributes": {
                "publishOn": "2024-11-26T15:03:08-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162809200/image_2162809200.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: MariTide Underwhelms, But There Are Ways To Win",
                "structuredInsights": "{ \"Key Takeaways\": [ \"The article discusses Amgen's MariTide trial results and evaluates the stock's potential despite underwhelming phase 2 data.\", \"Amgen's stock dropped due to disappointing MariTide data, but the company assures no bone safety concerns.\", \"MariTide offers dosing convenience with monthly administration, potentially aiding long-term adherence.\", \"Amgen's growth potential remains strong without MariTide's obesity pipeline upside.\", \"MariTide showed up to 20% weight loss in 52 weeks, aligning with competitors' results.\", \"\\\"I believe MariTide could become a viable competitor in the obesity, type 2 diabetes and adjacent markets.\\\"\" ], \"Positives\": [ \"MariTide's once-monthly dosing offers a competitive edge over weekly treatments.\", \"Amgen addresses safety concerns, claiming no bone mineral density impact.\", \"Positive data on glucose control and cardiovascular benefits in type 2 diabetes.\", \"\\\"Amgen's growth potential remains strong without MariTide's obesity pipeline upside.\\\"\" ], \"Concerns\": [ \"MariTide's 20% weight loss is underwhelming compared to market expectations.\", \"Safety and tolerability data are pending further presentations and publications.\", \"Potential competition from next-generation therapies may impact MariTide's market position.\", \"\\\"Market expectations were higher based on the phase 1 results and because MariTide is now less likely to be as competitive with next-generation therapies.\\\"\" ], \"Catalysts\": [ \"Future data presentations could reveal more on safety and tolerability.\", \"Phase 3 trials may show improved weight loss over extended periods.\", \"Once-monthly dosing could drive market adoption if approved.\", \"\\\"The stock is now down to pre-MariTide excitement levels, which, I believe, are attractive even based on the growth profile that excludes the upside of the obesity pipeline.\\\"\" ] }",
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "586525",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4740464-amgen-maritide-underwhelms-but-there-are-ways-to-win"
            }
        },
        {
            "id": "4738452",
            "type": "article",
            "attributes": {
                "publishOn": "2024-11-18T14:42:00-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324349/image_1418324349.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Sells Off: Keep Calm And Buy The Dip",
                "structuredInsights": "{ \"Key Takeaways\": [ \"The article discusses Amgen's recent stock sell-off and suggests buying the dip due to its undervaluation.\", \"Amgen's MariTide is a lead GLP-1 candidate with upcoming Phase II results that could be a major growth catalyst.\", \"Despite safety concerns raised, Amgen's management remains confident in MariTide's potential to meet unmet medical needs.\", \"Amgen's Q3 revenues increased 23% year-over-year, highlighting strong financial performance and growth prospects.\", \"Trading at 14.5x forward earnings, Amgen appears undervalued, especially with potential MariTide success.\", \"\\\"Shares of Amgen represent an asymmetric risk/reward profile currently, with ample upside if the company continues to execute.\\\"\" ], \"Positives\": [ \"Amgen is trading at 14.5x forward earnings, suggesting potential undervaluation.\", \"Phase II study for MariTide is progressing well, with management confident in its differentiated profile.\", \"Amgen's Q3 revenues increased 23% year-over-year, indicating strong financial performance.\", \"\\\"Amgen's management touts MariTide as a prime example of the company's execution.\\\"\" ], \"Concerns\": [ \"Safety concerns regarding MariTide's impact on bone mineral density could affect investor confidence.\", \"Amgen faces competition from companies like Eli Lilly and Novo Nordisk in the GLP-1 space.\", \"Success of MariTide is crucial for Amgen's market share and future growth prospects.\", \"\\\"Any loss in the drug's safety profile could make MariTide a non-starter.\\\"\" ], \"Catalysts\": [ \"Upcoming Phase II results for MariTide could significantly impact Amgen's stock price.\", \"Amgen's significant share reduction increases EPS, providing shareholder value.\", \"Analysts estimate MariTide has a 60% chance of approval, presenting potential growth.\", \"\\\"Shares of Amgen represent an asymmetric risk/reward profile currently.\\\"\" ] }",
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "584238",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4738452-amgen-sells-off-keep-calm-and-buy-the-dip"
            }
        },
        {
            "id": "4732576",
            "type": "article",
            "attributes": {
                "publishOn": "2024-11-03T11:18:03-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "580643",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4732576-amgen-biotech-giant-offering-value-growth-in-frothy-market"
            }
        },
        {
            "id": "4729572",
            "type": "article",
            "attributes": {
                "publishOn": "2024-10-25T10:29:49-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1195590742/image_1195590742.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "578694",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4729572-amgen-q3-earnings-review-many-questions-maritide-data-top-of-list"
            }
        },
        {
            "id": "4724105",
            "type": "article",
            "attributes": {
                "publishOn": "2024-09-30T01:32:51-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397335462/image_1397335462.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "572908",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4724105-prescription-for-dividends-why-amgen-is-more-than-just-a-safe-bet"
            }
        },
        {
            "id": "4723402",
            "type": "article",
            "attributes": {
                "publishOn": "2024-09-26T09:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "572203",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4723402-amgen-pipeline-updates-uplizna-performs-rocatinlimab-underwhelms-amgn-stock"
            }
        },
        {
            "id": "4717785",
            "type": "article",
            "attributes": {
                "publishOn": "2024-08-29T01:01:49-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's GLP-1 Upside Is Not Priced In",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "565622",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4717785-amgens-glp-1-upside-is-not-priced-in"
            }
        },
        {
            "id": "4717633",
            "type": "article",
            "attributes": {
                "publishOn": "2024-08-28T11:48:55-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Growth Is Still A Better Choice",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "565621",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4717633-amgen-growth-is-still-a-better-choice"
            }
        },
        {
            "id": "4712855",
            "type": "article",
            "attributes": {
                "publishOn": "2024-08-09T14:18:54-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/176233954/image_176233954.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Q2 Earnings Review: Still Solid, But Wait For MariTide Data Goes On",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "561376",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4712855-amgen-q2-earnings-review-still-solid-but-wait-for-maritide-data-goes-on"
            }
        },
        {
            "id": "4711405",
            "type": "article",
            "attributes": {
                "publishOn": "2024-08-07T08:00:21-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Shows Why Dividend Investing Is Getting Tougher",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59801",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "560630",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4711405-amgen-showing-why-dividend-investing-is-getting-tougher"
            }
        },
        {
            "id": "4702643",
            "type": "article",
            "attributes": {
                "publishOn": "2024-07-06T08:31:00-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "553757",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4702643-amgen-biotech-leader-riding-high-on-obesity-drug-euphoria-downgrade"
            }
        },
        {
            "id": "4702501",
            "type": "article",
            "attributes": {
                "publishOn": "2024-07-05T01:42:52-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "553542",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4702501-amgen-stock-emerging-glp-1-play-modest-mid-teens-pe-strong-momentum"
            }
        },
        {
            "id": "4699629",
            "type": "article",
            "attributes": {
                "publishOn": "2024-06-17T11:30:03-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227422521/image_1227422521.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: You Haven't Seen Anything Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "550105",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4699629-amgen-you-havent-seen-anything-yet"
            }
        },
        {
            "id": "4697206",
            "type": "article",
            "attributes": {
                "publishOn": "2024-06-04T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1194881737/image_1194881737.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "547200",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4697206-dont-be-a-doubter-amgen-is-a-fantastic-dividend-growth-stock-with-a-weightloss-wild-card"
            }
        },
        {
            "id": "4694852",
            "type": "article",
            "attributes": {
                "publishOn": "2024-05-21T16:27:16-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Stock: Poised To Break Out (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "544226",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4694852-amgen-stock-poised-to-break-out-technical-analysis"
            }
        },
        {
            "id": "4689415",
            "type": "article",
            "attributes": {
                "publishOn": "2024-05-04T09:13:02-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Could Become A Real Contender In The Obesity Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "540319",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4689415-amgen-could-become-real-contender-obesity-market"
            }
        },
        {
            "id": "4689189",
            "type": "article",
            "attributes": {
                "publishOn": "2024-05-03T13:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/493511655/image_493511655.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "540304",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4689189-amgens-q1-earnings-solid-all-court-progress-major-weight-loss-catalyst-pending"
            }
        },
        {
            "id": "4688193",
            "type": "article",
            "attributes": {
                "publishOn": "2024-05-01T17:07:44-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "539733",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4688193-amgen-stock-recent-weakness-is-not-a-buying-opportunity-yet"
            }
        },
        {
            "id": "4683764",
            "type": "article",
            "attributes": {
                "publishOn": "2024-04-15T08:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: I Prefer To Chase Value And Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "535957",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4683764-amgen-i-prefer-to-chase-value-and-dividends"
            }
        },
        {
            "id": "4683743",
            "type": "article",
            "attributes": {
                "publishOn": "2024-04-15T04:25:44-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401241138/image_1401241138.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: The Giant With An Impressive Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "535912",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4683743-amgen-the-giant-with-an-impressive-pipeline"
            }
        },
        {
            "id": "4681374",
            "type": "article",
            "attributes": {
                "publishOn": "2024-03-31T11:15:13-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183367047/image_183367047.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24627",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "532668",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4681374-move-over-eli-lilly-amgen-could-be-the-next-obesity-wonder-stock"
            }
        },
        {
            "id": "4677483",
            "type": "article",
            "attributes": {
                "publishOn": "2024-03-11T23:59:09-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491059980/image_1491059980.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Will Benefit From Increased Medical Spending",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107097",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "528764",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4677483-amgen-stock-will-benefit-from-increased-medical-spending"
            }
        },
        {
            "id": "4675628",
            "type": "article",
            "attributes": {
                "publishOn": "2024-03-04T07:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1867575053/image_1867575053.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Good Dividend Growth Stock For The Watch List",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "526845",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4675628-amgen-good-dividend-growth-stock-watch-list"
            }
        },
        {
            "id": "4671072",
            "type": "article",
            "attributes": {
                "publishOn": "2024-02-17T09:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4671072-spotlight-on-nvidia-walmart-palo-alto-networks-and-cagny-conference"
            }
        },
        {
            "id": "4668832",
            "type": "article",
            "attributes": {
                "publishOn": "2024-02-08T18:15:44-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "521695",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4668832-amgen-weight-loss-drug-candidate-debate-a-red-herring-buying-the-dip-advisable"
            }
        },
        {
            "id": "4666589",
            "type": "article",
            "attributes": {
                "publishOn": "2024-02-01T02:30:29-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442947197/image_1442947197.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Debt-Funded Buybacks Constrains Future Gains Per Share",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107169",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "519527",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4666589-amgen-debt-funded-buybacks-constrains-future-gains-per-share"
            }
        },
        {
            "id": "4665748",
            "type": "article",
            "attributes": {
                "publishOn": "2024-01-29T07:56:57-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182619005/image_1182619005.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Accelerating The Business And Dividend Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107154",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "518792",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4665748-amgen-accelerating-the-business-and-dividend-growth"
            }
        },
        {
            "id": "4664250",
            "type": "article",
            "attributes": {
                "publishOn": "2024-01-22T16:18:02-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/514773196/image_514773196.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "517329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4664250-up-40-percent-3-percent-yielding-amgen-is-still-one-of-my-favorite-healthcare-stocks"
            }
        }
    ]
}